Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Horm Res Paediatr ; 96(3): 298-305, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36220006

RESUMO

INTRODUCTION: Children with ADHD often present to pediatric endocrinologists due to growth concerns. Growth hormone stimulation testing (GHST) may be utilized as part of the workup. We evaluate whether children with ADHD and short stature or growth failure are more likely to fail GHST compared to children without ADHD. METHODS: We retrospectively studied children who underwent GHST as part of evaluation for short stature and/or growth failure and had an intact pituitary over a 16-year period (2002-2018). We performed univariate and logistic regression analyses with stratification by age. RESULTS: We included 260 children; 78 children had ADHD and were older, mean age (±SD) 12.2 (±2.6) years versus children without ADHD, mean age (±SD) 10.4 (±3.8) years. The population was largely Caucasian, and boys outnumbered the girls. Of the children with ADHD, only 9 were not medically treated. There was no difference in z-scores for height, weight, and BMI, or mid-parental height between the two groups. We found that children with ADHD were more likely to fail GHST than children without ADHD across the peak GH cut-offs of 10, 7, and 5 ng/mL (p = 0.003, p = 0.023, and p = 0.046 accordingly). The same trend persisted after regression analysis with adjustment for sex and stratification by age, and effect was more robust in the older group. DISCUSSION: The result shows higher likelihood of lower GH peaks in response to GHST in children with ADHD and short stature or impaired linear growth. Future work should evaluate possible mechanistic explanation and the role of psycho-stimulant medications.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade , Estimulantes do Sistema Nervoso Central , Nanismo , Hormônio do Crescimento Humano , Masculino , Feminino , Humanos , Criança , Adolescente , Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Estudos Retrospectivos , Estimulantes do Sistema Nervoso Central/uso terapêutico , Hormônio do Crescimento Humano/uso terapêutico , Hormônio do Crescimento/uso terapêutico , Nanismo/tratamento farmacológico
2.
Cardiol Young ; 32(6): 988-992, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-34657643

RESUMO

We report a case of thyroid storm precipitated by SARS-CoV-2 infection in an adolescent girl with a history of Graves disease and dilated cardiomyopathy. This case highlights that SARS-CoV-2 infection can potentially trigger a thyrotoxicosis crisis and acute decompensated heart failure in a patient with underlying thyroid disease and myocardial dysfunction even in the absence of multi-system inflammatory syndrome in children. We systematically reviewed the thyrotoxicosis cases with SARS-CoV-2 infection and described its impact on pre-existing dilated cardiomyopathy.


Assuntos
COVID-19 , Cardiomiopatia Dilatada , Insuficiência Cardíaca , Crise Tireóidea , Tireotoxicose , Adolescente , COVID-19/complicações , Criança , Feminino , Insuficiência Cardíaca/etiologia , Humanos , SARS-CoV-2 , Síndrome de Resposta Inflamatória Sistêmica , Crise Tireóidea/complicações , Crise Tireóidea/diagnóstico , Tireotoxicose/complicações , Tireotoxicose/diagnóstico
3.
Nutr Rev ; 73(9): 577-93, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26180255

RESUMO

CONTEXT: The independent or interactive effects of vitamin D and calcium on adiposity remain inconclusive. OBJECTIVE: The objective of this systematic review and meta-analysis was to assess whether vitamin D and calcium supplements cause changes in adiposity. DATA SOURCES: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials databases were searched for literature published from 1966 to March 2014. STUDY SELECTION: A systematic search was conducted for randomized clinical trials with ≥ 50 participants aged ≥ 18 years at baseline who had received at least 12 weeks of treatment. Among the inclusion criteria were supplementation with vitamin D with or without calcium and measurement of adiposity (weight, body mass index [BMI], and/or fat mass). DATA EXTRACTION: The primary endpoints assessed were changes in weight, BMI, or fat mass. DATA SYNTHESIS: Of 953 trials identified, 26 randomized clinical trials (n = 12, vitamin D alone; n = 10, vitamin D plus calcium versus calcium control; n = 4, vitamin D plus calcium versus placebo) with a total of 42,430 participants (median duration, 12 months) met the inclusion criteria. When compared with placebo, vitamin D supplementation had no significant effect on BMI (weighted mean difference [WMD], -0.06 kg/m(2); 95% confidence interval [95%CI], -0.14 to 0.03), weight (WMD, -0.05 kg; 95%CI, -0.32 to 0.23), or fat mass (WMD, -0.43 kg; 95%CI, -1.69 to 0.84). Likewise, no significant reduction in BMI (WMD, 0.02 kg/m(2); 95%CI, -0.11 to 0.14), weight (WMD, 0.12 kg; 95%CI, -0.24 to 0.49), or fat mass (WMD, 0.12 kg; 95%CI, -0.22 to 0.45) was observed in participants who received vitamin D plus calcium compared with those who received calcium control. CONCLUSIONS: Supplementation with vitamin D showed no effect on adiposity measures in adults.


Assuntos
Adiposidade/efeitos dos fármacos , Cálcio/administração & dosagem , Suplementos Nutricionais , Vitamina D/administração & dosagem , Vitaminas/administração & dosagem , Índice de Massa Corporal , Peso Corporal/efeitos dos fármacos , Humanos , Obesidade/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...